Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Giroctocogene fitelparvovec by Pfizer for Hemophilia A (Factor VIII Deficiency): Likelihood of Approval
Giroctocogene fitelparvovec is under clinical development by Pfizer and currently in Phase III for Hemophilia A (Factor VIII Deficiency). According...
Risk adjusted net present value: What is the current valuation of Pfizer's Giroctocogene fitelparvovec?
Giroctocogene fitelparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Pfizer's Giroctocogene fitelparvovec?
Giroctocogene fitelparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Hemophilia A (Factor VIII...